Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin J, Lin ZQ, Zheng SC, et al. Immune checkpoint inhibitor-associated gastritis: patterns and management. World J Gastroenterol. 2024;30:1941–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamada K, Sawada T, Nakamura M, et al. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. World J Gastroenterol. 2021;27:7190–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thapa B, Roopkumar J, Kim AS, et al. Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI). J Clin Oncol. 2019;37:e14151–e14151.

Article  Google Scholar 

Farha N, Faisal MS, Allende DS, et al. Characteristics of immune checkpoint inhibitor-associated gastritis: report from a major tertiary care center. Oncologist. 2023;28:706–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haryal A, Townsend MJ, Baskaran V, et al. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023;129:367–75.

Article  CAS  PubMed  Google Scholar 

Alomari M, Al Ashi S, Chadalavada P, et al. Gastrointestinal toxicities of immune checkpoint inhibitors are associated with enhanced tumor responsiveness and improved survival. Gastroenterol Res. 2022;15:56–66.

Article  CAS  Google Scholar 

Sugiyama Y, Tanabe H, Matsuya T, et al. Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review. Endosc Int Open. 2022;10:E982-E989.

PubMed  PubMed Central  Google Scholar 

Tang T, Abu-Sbeih H, Luo W, et al. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54:538–45.

Article  CAS  PubMed  Google Scholar 

Chen D, Zhao R, Cao W, et al. Clinical characteristics of cytomegalovirus gastritis: A retrospective study from a tertiary medical center. Medicine (Baltimore). 2020;99:e18927.

Article  PubMed  PubMed Central  Google Scholar 

Kakugawa Y, Kami M, Matsuda T, et al. Endoscopic diagnosis of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation. World J Gastroenterol. 2010;16:2907–12.

Article  PubMed  PubMed Central  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.

Article  PubMed  PubMed Central  Google Scholar 

Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15:458–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shivaji UN, Jeffery L, Gui X, et al. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol. 2019;12:1756284819884196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johncilla M, Grover S, Zhang X, et al. Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis. Histopathology. 2020;76:531–9.

Article  PubMed  Google Scholar 

Irshaid L, Robert ME, Zhang XJ, et al. Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, helicobacter pylori gastritis and celiac disease. Arch Pathol Lab Med. 2021;145:191–200.

Article  CAS  PubMed  Google Scholar 

El-Zimaity H, Choi W-T, Lauwers GY, et al. The differential diagnosis of Helicobacter pylori negative gastritis. Virchows Arch. 2018;473:533–50.

Article  PubMed  Google Scholar 

Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer. 2017;86:248–56.

Article  PubMed  Google Scholar 

Nakai M, Kai Y, Suzuki K, et al. A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy. Respir Med Case Rep. 2022;41:101794.

PubMed  PubMed Central  Google Scholar 

Amino Y, Uematsu S, Yoshizawa T, et al. A case involving careful control of cytomegalovirus infection during immunosuppressive therapy for severe immune-related adverse events caused by nivolumab. AJRS. 2021;10:33–6.

Google Scholar 

Tadokoro T, Tani J, Takamura K, et al. Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases. Kanzo. 2022;63:107–19.

Article  Google Scholar 

DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009;146:104–12.

Article  PubMed  Google Scholar